ArticleBritish journal of haematology2026
Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The study investigates how sex and age influence treatment response in paediatric, adolescent and young adult (AYA) classical Hodgkin lymphoma (cHL), integrating clinical data, immune-gene profiling and metabolic imaging from the European Network for Paediatric Hodgkin Lymphoma (EuroNet-PHL-C2 trial). cHL patients treated in Italian Association of Pediatric Hematology & Oncology Research (AIEOP) centres (2018-2020) underwent fluorodeoxyglucose-positron emission tomography (FDG-PET) at baseline, after two chemotherapy cycles early response assessment (ERA) and post-chemotherapy (late response assessment, LRA). Responses were classified as early complete metabolic response (CMR) or as adequate response (AR), inadequate (IR) or progressive disease at LRA. Tumour samples were profiled for 730 immune-related genes, and clinical and quantitative positron emission tomography parameters were integrated to assess sex- and age-related patterns. Sixty-eight cases passed quality control. Early CMR occurred in 51.5% at ERA; 29.4% showed (AR) at LRA. Older age (≥13 years), especially in males, was associated with higher IR risk. runt-related transcription factor 3 (RUNX3) expression characterized CMR; a five-gene panel (Bone Marrow Stromal Cell Antigen-1/CD157 [BST1]; C-X-C Motif Chemokine Receptor 6 [CXCR6]; Inducible T-cell Co-stimulator/CD278 [ICOS], Ubiquitin Specific Peptidase 9 Y-Linked [USP9Y], and Single Ig IL-1-Related Receptor/IL-1R8 [SIGIRR]) predicted IR and reflected sex-related immune differences. USP9Y expression correlated with baseline tumour volume (total metabolic tumour volume, TMTV1). Combining TMTV1 with RUNX3 improved CMR discrimination, while TMTV1 with the five-gene panel increased sensitivity but reduced accuracy at LRA. Sex and age influence immune response in AYA cHL. RUNX3 and the five-gene panel show promise as biomarkers of early and late response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.